Search

Message from the EHA Board

After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

Manage your membership

It's easy to amend your contact details or update your preferences. To get started, make sure you have your MyEHA log-in details. You can then follow the relevant steps below.

Read more

Registration

Register for the on-demand recordings

Individual registration
The virtual registration includes:

On-demand access to the recordings of the scientific and educational sessions of the meeting that took place 10-12 November, 2022.

Read more

Turning thoughts into reality

Turning thoughts into reality
By Dr Adi Zoref (@ZorefAdi)

I am an Israeli physician, trained in internal medicine. During my residency rotation in hematology at Meir Medical Center, I met a patient who changed my life.

Read more

About us

The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.

Read more

Board elections

Shape the future of EHA by taking part in our 2025 Board election. Nominations closed on February 9, 2025. The ballot will open on April 8, 2025.

Read more

EHA2023 Gallery

We extend our gratitude to the esteemed Faculty, delegates, and industry partners for their valuable contributions to the EHA2023 Hybrid Congress.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more